Håkan Brodin

The final phase in acute myeloid leukaemia (AML): A study on bleeding, infection and pain

To increase the knowledge of the final phase of acute myeloid leukaemia (AML) a retrospective review of the medical and nursing records of 106 adult patients with AML who had died in 1995-1997 was made. A total of 27 patients were treated with curative intent at the time of death and 79 patients were prescribed palliative care. From the documentation, an evaluation of the frequency and severity of bleeding and pain episodes was made during their last week in life, and the occurrence of infection criteria was studied. Notations on bleeding were found in 44%, infection in 71% and pain in 76% of the patients. In 54% of the morphine administration days, no information on the effect of given morphine treatment was registered. To give AML patients in the final phase, the best possible treatment, skills in palliative medicine and palliative care are important.

The final phase in acute myeloid leukaemia (AML): a study of cause of death, place of death and type of care during the last week of life

The aim of this study was to increase the knowledge of the final phase in acute myeloid leukaemia (AML), a period which entails many complex medical and psychosocial decisions. Data on cause and place of death were gathered through a retrospective review of medical and nursing records of 106 patients with AML who had died during 1995-1997. We focused on the actual phase of the disease and to what extent the patients were prescribed palliative care. With increased knowledge of the dying process in AML there are options to discuss which approach would be the most preferred final phase for an AML patient.

Cost analysis of different phases of acute myeloid leukaemia

Priority lists have been formulated in several countries and cut-backs can be a threat to leukaemia treatment. We analysed the costs in different phases of disease for 54 conventionally treated patients with acute myeloid leukaemia. Thirty-two patients reached CR 1, seven patients are still alive as of May 1994. We found a cost per week and patient of 17,334 Swedish Crowns (SEK) (U.K. 1 pound = 10.57 and U.S.

Assistive technology selection: a study of participation of users with rheumatoid arthritis

1 = 5.91, 1990) in induction phase, 1854 in remission phase and 10,529 SEK in relapse phase. In the terminal phase 10% of the total cost was spent. The quality of life of the patients in relapse is discussed and palliative treatment is emphasized.

Assessment of Rehabilitation Technologies in Stroke: Outcomes and Costs

A new program based on improved user participation for the selection of assistive devices was implemented and its effectiveness and efficiency assessed. The intervention was compared with traditional routines. The study population comprised persons with rheumatoid arthritis who lived in two communities in Sweden. The selection process yielded increased user participation, user satisfaction, an increased number of prescriptions, and consequently also higher costs. The outcome measures showed more vague improvements. No improvement in functional ability was found regarding pain and difficulty with daily activities in the two study groups, but an increased use of assistive devices was found among women below 64 years in the intervention group (p = 0.001). Women below 64 years in the intervention group rated an improved health-related quality of life regarding both the total score (p = 0.017) and the underlying dimensions of physical function (p = 0.012). Even though the intervention yielded positive results on process-variables as increased user participation and an increased number of prescribed assistive devices, only women below 64 years showed an increased use of assistive devices in daily activities and an improved health related quality of life.

Cost-Utility Analysis of Assistive Technologies in the European Commission's Tide Program

Initial functional ability (Barthel Index, mean 57) was found to be an important predictor of functional ability 1 year after stroke (mean 80) and for costs during the period. On average the total cost for a stroke patient was about SEK 200,000; the main expense, accommodation, averaged about SEK 140,000, while assistive devices amounted to SEK 2,600. Those who use assistive devices, although having achieved a high functional ability, perceive and rate their life situation (Nottingham Health Profile) considerably more impaired than those without assistive devices.

Mechanical Behaviour and Microstructure Correlation in a Selective Laser Melted Superalloy

Socioeconomic evaluation is an issue dealt with in the European Commissions research program TIDE. The principles of cost-utility analysis have been examined for usability in the assessment of rehabilitative technologies. A case study, the choice of a type of wheelchair, is described to demonstrate how estimates of utility can be derived and how cost-utility ratios can be used to guide decision making.

Assessment of computer-aided assistive technology: analysis of outcomes and costs

Selective laser melting (SLM), or, as the industry standard denotes the process, laser sintering, is an additive manufacturing process where metal powder is melted by a laser source layer-wise, for ...

3D Residual Stresses in Selective Laser Melted Hastelloy X

The objectives of this study were to identify and quantify outcomes related to implementation of computer-aided assistive technologies (CAAT) for individuals with communication disabilities and to ...

Cyclic Hot Corrosion of Thermal Barrier Coatings and Overlay Coatings

3D residual stresses in as manufactured EOS NickelAlloy HX, produced by laser powder bed additive manufacturing, are analysed on the surface closest to the build-plate. Due to the severe thermal gr ...